[Form 4] Equifax, Incorporated Insider Trading Activity
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
13 txns
Insider
Begor Mark W
Role
CEO
Sold
48,264 shs ($11.67M)
Approx. gross sale proceeds
$11.67M
Approx. exercise cost
$5.35M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option/Right to Buy | 27,960 | $0.00 | $0.00 |
| Exercise | Common Stock | 27,960 | $191.44 | $5.35M |
| Sale | Common Stock | 364 | $244.9479 | $89K |
| Sale | Common Stock | 831 | $243.9032 | $203K |
| Sale | Common Stock | 9,497 | $242.7014 | $2.30M |
| Sale | Common Stock | 17,731 | $241.8713 | $4.29M |
| Sale | Common Stock | 19,841 | $240.9462 | $4.78M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option/Right to Buy — 27,959 contracts (Direct);
Common Stock — 142,872 shares (Direct);
Common Stock — 10,500 shares (Indirect, 2-yr 2025 GRAT);
Common Stock — 9,525 shares (Indirect, 2-yr Feb 2024 GRAT);
Common Stock — 11,380 shares (Indirect, 2-yr Jul 2024 GRAT);
Common Stock — 43,431 shares (Indirect, 2-yr Jun 2025 GRAT);
Common Stock — 12,333 shares (Indirect, 2-yr May 2025 GRAT);
Common Stock — 16,287 shares (Indirect, 3-yr Jul 2024 GRAT)
Footnotes (8)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/14/2024.
- F2. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $244.72 to $245.33, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F3. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 199 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.
- F4. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $243.47 to $244.44, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F5. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $242.41 to $243.17, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F6. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $241.41 to $242.40, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F7. The price reported in column 4 is a weighted average price. The shares were sold at prices ranging from $240.40 to $241.39, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price will be provided.
- F8. The option vested in three equal annual increments beginning 2/21/2021.
AI-generated analysis. How Rhea-AI works. Not financial advice.
